Biomed Lublin Wytwornia Surowic I Szczepionek SA operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biomed Lublin Wytwornia Surowic I Szczepionek SA with three other
pharmaceutical manufacturers in Europe:
sales of 8.53 million Euro [US$9.67 million]
(7.46 million Euro [US$8.45 million]
of which 72%
was Research & Development Tax Credit), and
based in Germany
(6.80 million Euro [US$7.70 million]
Biomed Lublin Wytwornia Surowic I Szczepionek SA reported sales of 31.40 million Polish New Zlotys (US$8.30 million)
December of 2017.
decrease of 13.6%
versus 2016, when the company's sales were 36.34 million Polish New Zlotys.
Contributing to the drop in overall sales was the 93.6% decline
in Traditional Segment, from 27.61 million Polish New Zlotys to 1.78 million Polish New Zlotys.
However, these declines were partially offset by the increase in sales of
Plasma Segment (up 239.5% to 29.63 million Polish New Zlotys)